The Outcomes of Primary Debulking Surgery and Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Abstract

Objective: To compare the outcomes and survival rate of primary
 debulking surgery with neoadjuvant chemotherapy.
 Method: We selected advanced ovarian cancer patients from medical
 records. Subjects were allocated into groups of primary debulking
 surgery and neoajuvant chemotherapy by considering the inclusion
 and exclusion criteria. We analyzed the data using T test,
 Fisher’s exact, and chi-square. The survival rate was presented in
 Kaplan Meier curve, whereas the significance was tested with Logrank.
 We managed the data using STRATA software version 12.
 Result: We obtained 32 cases of primary debulking surgery group
 and 20 cases of the neoadjuvant chemotherapy group. Most of the
 subjects (44.2%) were 40-49 years old and 80.8% had delivered
 more than twice. The mean value of Ca-125 at admission was
 3,594.8 u/ml (range 66.6 to 73,000 u/ml). Total of 31 subjects
 showed the serous histologic type (59.6%). There was no association
 between primary debulking surgery and neoadjuvant chemotherapy
 for the parameter of operative time, blood loss, organs injury,
 ICU stay, and hospital stay (p>0.05). Primary debulking surgery
 had a survival rate similar to neoadjuvant chemotherapy group
 (p=0.95).
 Conclusion: The perioperative outcomes of advanced ovarian cancer
 patients has similar result between primary debulking surgery
 and neoadjuvant chemotherapy. Primary debulking surgery has a
 survival rate similar to neoadjuvant chemotherapy group.
 [Indones J Obstet Gynecol 2016; 4-2: 111-115]
 Keywords: advanced ovarian cancer, neoadjuvant chemotherapy,
 primary debulking surgery